𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors

✍ Scribed by Leanne M. Kmet; Linda S. Cook; Anthony M. Magliocco

Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
223 KB
Volume
97
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

BACKGROUND

In the current study, the authors present pooled data from studies that investigated p53 protein expression and/or mutation in human epithelial ovarian tumors.

METHODS

The English literature in the MEDLINE, PubMed, and Ingenta databases was searched to the end of the year 2000 to identify relevant studies. Data were pooled across eligible studies, and the prevalence of p53 expression and mutation among benign, low malignant potential (LMP), and invasive tumors was determined. Prevalence estimates by tumor histology, International Federation of Gynecology and Obstetrics (FIGO) stage, and grade also were calculated.

RESULTS

The pooled prevalence estimate for p53 overexpression among epithelial ovarian carcinomas was 51% (95% confidence intervals [95% CI], 50–53%) compared with 17% (95% CI, 15–20%) among LMP tumors and 7% (95% CI, 5–10%) among benign tumors. p53 mutation prevalence estimates were 45% (95% CI, 42–47%), 5% (95% CI, 2–9%), and 1% (95% CI, 0–5%), respectively, for invasive, LMP, and benign tumors. The prevalence of these p53 abnormalities was found to be associated positively with increasing tumor grade and stage. Differences based on histologic subtype also were found.

CONCLUSIONS

Although these pooled estimates might appear to offer support for various hypotheses regarding the role of p53 in ovarian carcinoma, the limitations inherent in these data hamper the interpretation of the significance of any of the findings. Future studies will require innovative methods to address the limitations of many previous investigations and more comprehensive investigation into defective tumor suppression mechanisms. Cancer 2003;97:389–404. Β© 2003 American Cancer Society.

DOI 10.1002/cncr.11064

πŸ“œ SIMILAR VOLUMES

Expression of human telomerase subunits
Expression of human telomerase subunits in ovarian malignant, borderline and benign tumors
✍ Satoru Kyo,; Taro Kanaya; Masahiro Takakura; Masaaki Tanaka; Atsuko Yamashita; H πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 French βš– 105 KB πŸ‘ 2 views

Telomerase activity is involved in the maintenance of telomere length and is thought to be required for cellular immortality and oncogenesis. Three major subunits composing telomerase, human telomerase RNA (hTR), telomeraseassociated protein (TP1) and human telomerase catalytic subunit (hTERT), have

Expression of FHIT in primary cultures o
Expression of FHIT in primary cultures of human epithelial ovarian tumors and malignant ovarian ascites
✍ Andrew P. Manning; Anne-Marie Mes-Masson; Robert J. Seymour; Melanie Tetrault; D πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 176 KB πŸ‘ 2 views

Abnormal FHIT gene expression has been reported in a variety of epithelial tumors shown to harbor deletions of chromosome 3p14, the chromosomal assignment of this gene. Recently, we described loss of heterozygosity of 3p in a subset of epithelial ovarian cancers. To investigate a potential role of t

Aberrant promoter methylation of multipl
Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential
✍ Andrew Wiley; Dionyssios Katsaros; Haigang Chen; Irene A. Rigault de la Longrais πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 217 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Methylation‐mediated suppression of detoxification, DNA repair, and tumor suppressor genes has been implicated in cancer development and progression. Studies also have indicated that concordant methylation of multiple genes (methylator phenotypes), rather than a single g